

## COMPANY OVERVIEW

VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's three CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

## RECENT NEWS

### [VistaGen Therapeutics Set to Join the Russell 2000® Index](#)

Jun 16 2021, 8:00 AM EDT

## STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	549.69m
Last Price	\$2.89
52-Week Range	\$0.46 - \$3.18

06/18/2021 04:00 PM EDT

## INVESTOR RELATIONS

### VistaGen Therapeutics, Inc.

Mark McPartland  
Vice President, Corporate Development  
+1(650) 577-3606  
[markmcp@vistagen.com](mailto:markmcp@vistagen.com)

VistaGen Therapeutics  
Mark Flather  
Vice President, Investor Relations  
+1(650) 577-3617  
[mflather@vistagen.com](mailto:mflather@vistagen.com)

## MANAGEMENT TEAM

### Shawn K. Singh, J.D.

Chief Executive Officer and Director

### H. Ralph Snodgrass, Ph.D.

Founder, President, Chief Scientific Officer and Director

### Mark A. Smith, M.D., Ph.D.

Chief Medical Officer

### Ann Cunningham, MBA

Chief Commercial Officer and Director

### Jerrold D. Dotson, CPA

Vice President, Chief Financial Officer and Secretary

### Mark J. Ginski, Ph.D.

Senior Vice President, Head of CMC

### Mark A. McPartland

Vice President of Corporate Development

### Louis Monti, M.D., Ph.D.

Vice President, Translational Medicine

---

## VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue  
South San Francisco, CA 94080

---

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.